Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

2상 완료 NCT00821821

요약

The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

Number of Participants That Experienced Adverse Events

87days · participants

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain — Prasad Shirvalkar, MD, PhD
• Women's Health Initiative Strong and Healthy Study — Fred Hutchinson Cancer Center
• Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke — Shionogi
• Zambia Stroke Unit Study — Johns Hopkins University
• Tracking Post-stroke Walking Improvements From the Clinic Into the Home — Western University of Health Sciences
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

전체 임상